BACKGROUND. There is no effective pharmacologic treatment for Alzheimer's disease, the most common dementing illness in the United States. Hydergine, a combination of ergoloid mesylates, is the only approved medication for Alzheimer's disease, but despite widespread use its efficacy remains to be established. We conducted a clinical trial of Hydergine-LC, a newer preparation of ergoloid mesylates in the form of a liquid in a capsule (LC) that may have greater bioavailability, to determine its value in patients with Alzheimer's disease. METHODS AND RESULTS. Eighty older adults with probable Alzheimer's disease participated in this double-blind, placebo-controlled trial of Hydergine-LC for 24 weeks. The recommended dose of 1 mg orally three times daily was used. Cognition and behavior were evaluated before and after the trial, and the patients were monitored for adverse effects. The medication was safe and well tolerated. The Hydergine-LC group did not perform better after treatment than the placebo group on any test, and its performance was worse (P less than 0.01 and P less than 0.02, respectively) on one cognitive measure (Wechsler Adult Intelligence Scale Digit Symbol Substitution Task) and on one behavioral scale (the Geriatric Evaluation by Relatives Rating Instrument). CONCLUSIONS. Hydergine-LC appears to be ineffective as a treatment for Alzheimer's disease.
Source Information
Department of Psychiatry, University of Colorado School of Medicine, Denver.
This article has been cited by other articles:
Belgeri, M., Morley, J. E.
(2004). A Step Back in Time: Is There a Place for Older Drugs in the Treatment of Dementia?. Journals of Gerontology Series A: Biological Sciences and Medical Sciences
59: M1025-M1028
[Full Text]
Doody, R. S., Stevens, J.C., Beck, C., Dubinsky, R.M., Kaye, J.A., Gwyther, L., Mohs, R.C., Thal, L.J., Whitehouse, P.J., DeKosky, S.T., Cummings, J.L.
(2001). Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology
56: 1154-1166
[Abstract][Full Text]
Eccles, M., Clarke, J., Livingston, M., Freemantle, N., Mason, J.
(1998). North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ
317: 802-808
[Full Text]
Larson, E. B.
(1998). New Drug Treatments for Alzheimer Disease. Arch Intern Med
158: 941-942
[Full Text]
Knopman, D. S., Morris, J. C.
(1997). An Update on Primary Drug Therapies for Alzheimer Disease. Arch Neurol
54: 1406-1409
[Abstract]
Patel, S. V.
(1995). Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review. J Geriatr Psychiatry Neurol
8: 81-95
[Abstract]
Allen, N.H.P., Burns, A.
(1995). The treatment of Alzheimer's disease. J Psychopharmacol
9: 43-56
Schneider, L. S., Olin, J. T.
(1994). Overview of Clinical Trials of Hydergine in Dementia. Arch Neurol
51: 787-798
[Abstract]
Gurwitz, J. H.
(1994). Suboptimal Medication Use in the Elderly: The Tip of the Iceberg. JAMA
272: 316-317
[Abstract]
Larson, E. B.
(1991). Geriatric Medicine. JAMA
265: 3125-3126
[Abstract]
Baer, L., Jenike, M. A., Mitchell, W. D., Filley, C. M., Thompson, T. L.
(1991). Correspondence. J Geriatr Psychiatry Neurol
4: 122-123
Cooper, J. K.
(1991). Drug Treatment of Alzheimer's Disease. Arch Intern Med
151: 245-249
[Abstract]
McPherson, M. L.
(1991). Alzheimer's disease: Definition and therapy options. Home Health Care Management Practice
3: 1-5
[Abstract]
(1990). HYDERGINE MAY BE INEFFECTIVE IN ALZHEIMER'S DISEASE. JWatch General
1990: 2-2
[Full Text]
Previous
